Interferon tau
Also known as: IFN-τ, IFNT, Interferon tau, oIFN-τ, Ovine interferon tau, Pregnancy recognition signal, Trophoblast interferon
Source Interferon tau at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Interferon tau (IFN‑τ) is a ruminant‑specific type I interferon secreted by trophoblast cells during early pregnancy. It mediates maternal immune tolerance and displays antiviral activity in vitro. No human or veterinary therapeutic approval exists; it is used only in experimental settings.
Mechanism of Action
Binds the IFNAR1/IFNAR2 receptor complex, activating JAK1 and TYK2, which phosphorylate STAT1/STAT2 and induce transcription of interferon‑stimulated genes, producing antiviral, antiproliferative, and immunomodulatory effects.
Routes of Administration
Goals & Uses
- Antiviral therapyInfectious DiseaseLow
- Multiple sclerosis treatmentAutoimmune / NeuroinflammatoryLow
- Enhance embryo implantationReproductiveModerate
- Lupus / SLEAutoimmuneUnknown
- Antiviral activityInfectious DiseaseLow
- Immunomodulation in autoimmune diseasesAutoimmuneLow
- Inflammatory bowel diseaseGastroenterologyLow
Contraindications
- Severe hepatic impairmentOrganModerateLiver function concerns
- Severe psychiatric disordersPsychiatricModerate
- Autoimmune hepatitisHepatic / AutoimmuneHigh
- Hypersensitivity to interferon tau or excipientsAllergy / ImmunologicHigh
Adverse Effects
- HepatotoxicityHepaticUncommonLiver injury or dysfunction
- Flu‑like symptomsSystemicUnknown
- Injection site reactionsLocalCommon
- Flu-like symptoms (fever, chills, myalgia)SystemicCommon
- Neuropsychiatric effectsNeurological / PsychiatricUncommon
- Hematologic changes (leukopenia, thrombocytopenia)HematologicUncommon
- FatigueGeneralCommonLow energy or tiredness
Drug Interactions
- Myelosuppressive agentsModerate
- Immunosuppressants (e.g., corticosteroids)Moderate
- Hepatotoxic drugsModerate
Population Constraints
- PregnancyReproductive SafetyRelative
- Renal impairmentOrgan ImpairmentRelative
- Pediatric populationsAgeRelative
- Pre-existing autoimmune conditionsAutoimmuneRelative
- Non‑ruminant speciesSpeciesRelative
Regulatory Status
- European UnionUnapprovedNo EMA marketing authorization.
- United StatesUnapprovedInvestigational only; no FDA clearance.
- United KingdomInvestigationalNo MHRA approval; research use only
No regulatory approval for human or animal use; employed solely in pre‑clinical and veterinary research.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Interferon tau?
Interferon tau (IFN‑τ) is a ruminant‑specific type I interferon secreted by trophoblast cells during early pregnancy. It mediates maternal immune tolerance and displays antiviral activity in vitro. No human or veterinary therapeutic approval exists; it is used only in experimental settings.
What is Interferon tau used for?
Interferon tau is educationally associated with: Antiviral therapy, Multiple sclerosis treatment, Enhance embryo implantation, Lupus / SLE, Antiviral activity, Immunomodulation in autoimmune diseases, Inflammatory bowel disease. Educational only — not medical advice.
How is Interferon tau administered?
Recorded routes of administration: Intramuscular, Intravenous, Oral, Subcutaneous.
What are the potential side effects of Interferon tau?
Reported adverse effects include: Hepatotoxicity, Flu‑like symptoms, Injection site reactions, Flu-like symptoms (fever, chills, myalgia), Neuropsychiatric effects, Hematologic changes (leukopenia, thrombocytopenia), Fatigue. This list is not exhaustive — consult a qualified clinician.
Who should avoid Interferon tau?
Recorded contraindications: Severe hepatic impairment, Severe psychiatric disorders, Autoimmune hepatitis, Hypersensitivity to interferon tau or excipients. Consult a qualified clinician before use.